Cerdulatinib HCl

产品说明书

Print
Chemical Structure| 1369761-01-2 同义名 : PRT2070 hydrochloride; PRT062070 hydrochloride; Cerdulatinib hydrochloride
CAS号 : 1369761-01-2
货号 : A356094
分子式 : C20H28ClN7O3S
纯度 : 99%+
分子量 : 482.0
MDL号 : MFCD28348366
存储条件：

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：

IP 4% DMSO+water 1 mg/mL clear

PO 0.5% CMC-Na 23 mg/mL suspension

生物活性
描述 Cerdulatinib hydrochloride (PRT062070) is a selective, orally bioavailable, and reversible ATP-competitive inhibitor targeting both SYK and JAK kinases, with IC50 values of 32 nM for SYK, and impressively low IC50s of 0.5 nM, 12 nM, 6 nM, and 8 nM for Tyk2, JAK1, JAK2, and JAK3, respectively. This dual inhibition profile positions cerdulatinib hydrochloride as a promising candidate for the study of autoimmune diseases and B-cell malignancies[1].[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.37mL

2.07mL

1.04mL

20.75mL

4.15mL

2.07mL
参考文献

[1]Coffey G, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014 Dec; 351(3): 538-48.

[2]Ishikawa C, et, al. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Int J Oncol. 2018 Oct; 53(4): 1681-1690.